

Glioblastoma Multiforme (GBM) Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drugs (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-08-21 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Glioblastoma Multiforme (GBM) Treatment Market Analysis and Insights

The Glioblastoma Multiforme (GBM) Treatment Market size is anticipated to reach USD 2.52 Billion in 2022 and it is projected to reach USD 5.29 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Glioblastoma Multiforme (GBM) Treatment Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Glioblastoma Multiforme (GBM) Treatment Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing. Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Glioblastoma Multiforme (GBM) Treatment Market includes major supplies & Independent Consultants among others.

Global Market Scope and Glioblastoma Multiforme (GBM) Treatment Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Glioblastoma Multiforme (GBM) Treatment Market trends from 2024 to 2032 underlying in specific geographies.

Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Glioblastoma Multiforme (GBM) Treatment Market Country Level Analysis

The Global Glioblastoma Multiforme (GBM) Treatment Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Glioblastoma Multiforme (GBM) Treatment Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Glioblastoma Multiforme (GBM) Treatment Market

Some of the other major highlights of the demand for Glioblastoma Multiforme (GBM) Treatment Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Glioblastoma Multiforme (GBM) Treatment Market during the forecast period.

Merck &Co. Inc.

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

Amgen Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Arbor Pharmaceuticals LLC

Karyopharm Therapeutics Inc.

Amneal Pharmaceuticals

Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.).

Market Segmentation

The Global Glioblastoma Multiforme (GBM) Treatment Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Treatment

Surgery

Radiation Therapy

Chemotherapy

Targeted Therapy

Tumor Treating Field (TTF) Therapy

Immunotherapy

By Drugs

Temozolomide

Bevacizumab

Lomustine

Carmustine Wafers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Others

By End-User

Hospitals

Clinics

Ambulatory Surgical Centers

Regions Coverd

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Italy

Russia

Nordic

Benelux

Rest of Europe

APAC

China

Korea

Japan

India

Australia

Singapore

Taiwan

South East Asia

Rest of Asia-Pacific

Middle East and Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6 Global Glioblastoma Multiforme (GBM) Treatment Market Size Analysis

6.1 By Treatment

6.1.1 Surgery

6.1.2 Radiation Therapy

6.1.3 Chemotherapy

6.1.4 Targeted Therapy

6.1.5 Tumor Treating Field (TTF) Therapy

6.1.6 Immunotherapy

6.2 By Drugs

6.2.1 Temozolomide

6.2.2 Bevacizumab

6.2.3 Lomustine

6.2.4 Carmustine Wafers

6.2.5 Others

6.3 By End-User

6.3.1 Hospitals

6.3.2 Clinics

6.3.3 Ambulatory Surgical Centers

7 North America Market Analysis

7.1 By Treatment

7.1.1 Surgery

7.1.2 Radiation Therapy

7.1.3 Chemotherapy

7.1.4 Targeted Therapy

7.1.5 Tumor Treating Field (TTF) Therapy

7.1.6 Immunotherapy

7.2 By Drugs

7.2.1 Temozolomide

7.2.2 Bevacizumab

7.2.3 Lomustine

7.2.4 Carmustine Wafers

7.2.5 Others

7.3 By End-User

7.3.1 Hospitals

7.3.2 Clinics

7.3.3 Ambulatory Surgical Centers

7.3 U.S.

7.4 Canada

8 Europe Market Analysis

8.1 By Treatment

8.1.1 Surgery

8.1.2 Radiation Therapy

8.1.3 Chemotherapy

8.1.4 Targeted Therapy

8.1.5 Tumor Treating Field (TTF) Therapy

8.1.6 Immunotherapy

8.2 By Drugs

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.1 Temozolomide
- 8.2.2 Bevacizumab
- 8.2.3 Lomustine
- 8.2.4 Carmustine Wafers
- 8.2.5 Others
- 8.3 By End-User
 - 8.3.1 Hospitals
 - 8.3.2 Clinics
 - 8.3.3 Ambulatory Surgical Centers
- 8.3 U.K.
- 8.4 Germany
- 8.5 France
- 8.6 Spain
- 8.7 Italy
- 8.8 Russia
- 8.9 Nordic
- 8.10 Benelux
- 8.11 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Treatment
 - 9.1.1 Surgery
 - 9.1.2 Radiation Therapy
 - 9.1.3 Chemotherapy
 - 9.1.4 Targeted Therapy
 - 9.1.5 Tumor Treating Field (TTF) Therapy
 - 9.1.6 Immunotherapy
 - 9.2 By Drugs
 - 9.2.1 Temozolomide
 - 9.2.2 Bevacizumab
 - 9.2.3 Lomustine
 - 9.2.4 Carmustine Wafers
 - 9.2.5 Others
 - 9.3 By End-User
 - 9.3.1 Hospitals
 - 9.3.2 Clinics
 - 9.3.3 Ambulatory Surgical Centers
 - 9.3 China
 - 9.4 Korea
 - 9.5 Japan
 - 9.6 India
 - 9.7 Australia
 - 9.8 Taiwan
 - 9.9 South East Asia
 - 9.10 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Treatment
 - 10.1.1 Surgery

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.2 Radiation Therapy
- 10.1.3 Chemotherapy
- 10.1.4 Targeted Therapy
- 10.1.5 Tumor Treating Field (TTF) Therapy
- 10.1.6 Immunotherapy
- 10.2 By Drugs
 - 10.2.1 Temozolomide
 - 10.2.2 Bevacizumab
 - 10.2.3 Lomustine
 - 10.2.4 Carmustine Wafers
 - 10.2.5 Others
- 10.3 By End-User
 - 10.3.1 Hospitals
 - 10.3.2 Clinics
 - 10.3.3 Ambulatory Surgical Centers
- 10.3 UAE
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 South Africa
- 10.7 Egypt
- 10.8 Nigeria
- 10.9 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Treatment
 - 11.1.1 Surgery
 - 11.1.2 Radiation Therapy
 - 11.1.3 Chemotherapy
 - 11.1.4 Targeted Therapy
 - 11.1.5 Tumor Treating Field (TTF) Therapy
 - 11.1.6 Immunotherapy
 - 11.2 By Drugs
 - 11.2.1 Temozolomide
 - 11.2.2 Bevacizumab
 - 11.2.3 Lomustine
 - 11.2.4 Carmustine Wafers
 - 11.2.5 Others
 - 11.3 By End-User
 - 11.3.1 Hospitals
 - 11.3.2 Clinics
 - 11.3.3 Ambulatory Surgical Centers
 - 11.3 Brazil
 - 11.4 Mexico
 - 11.5 Argentina
 - 11.6 Chile
 - 11.7 Colombia
 - 11.8 Rest of LATAM
- 12 Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1 Global Glioblastoma Multiforme (GBM) Treatment Market Share By Players
- 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments
 - 13.2 F. Hoffmann-La Roche Ltd.
 - 13.3 Pfizer Inc.
 - 13.4 Amgen Inc.
 - 13.5 Sun Pharmaceutical Industries Ltd.
 - 13.6 Teva Pharmaceutical Industries Ltd.
 - 13.7 Arbor Pharmaceuticals LLC
 - 13.8 Karyopharm Therapeutics Inc.
 - 13.9 Amneal Pharmaceuticals
 - 13.10 Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.).
- 14 Research Methodology
 - 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
 - 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
 - 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
 - 14.3 Research Assumptions
 - 14.3.1 Assumptions
 - 14.4 Limitations
 - 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Glioblastoma Multiforme (GBM) Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drugs (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-08-21 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*		City*	
Zip Code*		Country*	
		Date	2026-02-22
		Signature	